Canada markets closed

Aptose Biosciences Inc. (APS.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
1.0700-0.0200 (-1.83%)
At close: 03:59PM EDT

Aptose Biosciences Inc.

251 Consumers Road
Suite 1105
Toronto, ON M2J 4R3

Full Time Employees41

Key Executives

NameTitlePayExercisedYear Born
Dr. William G. Rice Ph.D.Chairman, Pres, CEO & Chief Accounting Officer918.46kN/A1959
Dr. Rafael Bejar M.D., Ph.D.Sr. VP & Chief Medical Officer624.7kN/A1972
Ms. Janet Clennett C.A.VP of Fin.N/AN/AN/A
Mr. Fletcher PayneSr. VP & CFON/AN/A1963
Mr. Roger Davies B.Sc.VP of OperationsN/AN/AN/A
Mr. Philippe LedruSr. VP & Chief Commercial OfficerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Corporate Governance

Aptose Biosciences Inc.’s ISS Governance QualityScore as of July 31, 2022 is 9. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 7; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.